Stock Events

Stock Events

Carisma Therapeutics 

$0.000700
118
-$0.00-22.22% 13:35 Today

Statistics

Day High
0.0324
Day Low
0.0263
52W High
0.44
52W Low
0.0001
Volume
10,296
Avg. Volume
25,585
Mkt Cap
29,291.5
P/E Ratio
0.03
Dividend Yield
-
Dividend
-

Dividends

0%Dividend Yield
Mar 23
$0.18
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

7MayExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
-0.32
-0.24
-0.17
-0.09
Expected EPS
-0.1474
Actual EPS
N/A

Financials

-308.05%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
19.63MRevenue
-60.48MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CARM. It's not an investment recommendation.
NVIDIA
11
NVDA
Coca-Cola
10
KO
Microsoft
9
MSFT
Johnson & Johnson
9
JNJ

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Allogene Therapeutics
ALLO
Mkt Cap697.89M
Allogene Therapeutics is involved in the development of allogeneic CAR T therapies for cancer, similar to Carisma's focus on innovative cancer treatments.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is engaged in gene editing and CAR-T cell therapies, competing in the advanced therapy medicinal products (ATMPs) space like Carisma.
Novartis
NVS
Mkt Cap292.35B
Novartis is a major player in the CAR T-cell therapy market with approved products, representing significant competition for Carisma in terms of market share and innovation.
Precigen
PGEN
Mkt Cap2.49B
Precigen is a biotechnology company that develops CAR-T and other gene and cell therapies, competing in the same space as Carisma for novel cancer treatments.

About

Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others. In addition, it develops in vivo CAR-M cell therapy to treat solid tumors, including hepatocellular carcinoma. Carisma Therapeutics, Inc. has collaboration and license agreement with ModernaTX, Inc. to address oncology gene therapies. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. Carisma Therapeutics, Inc. was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.
Show more...
CEO
Craig R. Jalbert
Employees
46
Country
United States
ISIN
US14216R1014
WKN
000A3DZG2

Listings

MU
DE
W2J.MU
OTC Link
US
CARM

0 Comments

Share your thoughts

FAQ

What is Carisma Therapeutics stock price today?▼
The current price of CARM is $0.00 USD — it has decreased by -22.22% in the past 24 hours. Watch Carisma Therapeutics stock price performance more closely on the chart.
What is Carisma Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Carisma Therapeutics stocks are traded under the ticker CARM.
Is Carisma Therapeutics stock price growing?▼
CARM stock has fallen by -46.15% compared to the previous week, the month change is a -72% fall, over the last year Carisma Therapeutics has showed a -99.78% decrease.
What is Carisma Therapeutics market cap?▼
Today Carisma Therapeutics has the market capitalization of 29,291.5
What is Carisma Therapeutics revenue for the last year?▼
Carisma Therapeutics revenue for the last year amounts to 19.63M USD.
What is Carisma Therapeutics net income for the last year?▼
CARM net income for the last year is -60.48M USD.
Does Carisma Therapeutics pay dividends?▼
Yes, CARM dividends are paid en. The last dividend per share was 0.18 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Carisma Therapeutics have?▼
As of September 04, 2026, the company has 46 employees.
In which sector is Carisma Therapeutics located?▼
Carisma Therapeutics operates in the Health & Wellness sector.
When did Carisma Therapeutics complete a stock split?▼
The last stock split for Carisma Therapeutics was on March 08, 2023 with a ratio of 2:1.
Where is Carisma Therapeutics headquartered?▼
Carisma Therapeutics is headquartered in Philadelphia, United States.